Clincosm LogoSign in Get a demo

METPSDS: MiRNAs Evaluate the Prognosis of Sepsis by Dynamic Study

Sponsor
Chinese PLA General Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01459822
Collaborator
(none)
70
Enrollment
1
Location
25
Duration (Months)
2.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to observe the selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis in order to be a new target for the treatment of sepsis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study is a non-intervention observational study. Purpose of this study is to observe some selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis . The investigators will collect serum samples from patients with sepsis in SICU, RICU and EICU on the 1st、3rd、5th、7th、10th、14th day of 301 Hospital since November 2011 , and then use mirVana PARIS kit extract total RNA and use qRT-PCR detect miRNAS expression in serum which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    70 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    MiRNAhs in the Evaluation of the Value of Sepsis Prognosis Dynamics Observational Research
    Study Start Date :
    Aug 1, 2011
    Anticipated Primary Completion Date :
    Jul 1, 2013
    Anticipated Study Completion Date :
    Sep 1, 2013

    Arms and Interventions

    Arm Intervention/Treatment
    Survival Group
    Death Group

    Outcome Measures

    Primary Outcome Measures

    1. all cause mortality [28days after admited in ICU]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Clinical diagnosis of sepsis

    • Patients who agree with the study

    Exclusion Criteria:

    • Aged <18 years;

    • Into the group who died within 24 hours;

    • Agranulocytosis (<0.5 × 109 / L);

    • Combined HIV infection.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chinese PLA General Hospital Beijing Haidian China 100853

    Sponsors and Collaborators

    • Chinese PLA General Hospital

    Investigators

    • Study Director: LiXin Xie, doctor, Pneumology Department of chinese PLA General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01459822
    Other Study ID Numbers:
    • 301PLAGH-20110824005
    First Posted:
    Oct 26, 2011
    Last Update Posted:
    Oct 26, 2011
    Last Verified:
    Aug 1, 2011
    Keywords provided by , ,
    sepsis
    miRNA
    Additional relevant MeSH terms:
    Sepsis
    Toxemia

    Study Results

    No Results Posted as of Oct 26, 2011